Overview

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

This study aims to evaluate whether the use of a 25 mg dose of empagliflozin compared to the 10 mg dose used would bring additional benefits in the improvement outcomes of the Kansas City Cardiomyopathy Questionnaire (KCCQ SST), in the 6-minute walk test (6MWT) without causing significant side effects.

Phase:

PHASE3

Details

Lead Sponsor:

Conrado Roberto Hoffmann Filho

Treatments:

empagliflozin